Interferon λ4

Interferon lambda 4 (IFN-λ4) is a type of interferon, a group of signaling proteins made and released by host cells in response to the presence of several viruses. IFN-λ4 is part of the type III interferon family, which also includes IFN-λ1, IFN-λ2, and IFN-λ3. These cytokines play a crucial role in the immune response to viral infections, particularly in the liver and epithelial tissues.

Discovery and Genetics[edit]

IFN-λ4 was discovered in 2013 as a result of genome-wide association studies (GWAS) that linked a genetic variant near the IFNL3 gene (formerly known as IL28B) to the response to hepatitis C virus (HCV) treatment. The discovery of IFN-λ4 was significant because it provided a molecular explanation for the genetic association with HCV clearance.

The IFNL4 gene is located on chromosome 19 in humans, and its expression is regulated by a dinucleotide polymorphism (TT/ΔG) in the first exon. The ΔG allele creates an open reading frame that allows the production of the IFN-λ4 protein, whereas the TT allele results in a frameshift that prevents its production.

Structure and Function[edit]

IFN-λ4 is a cytokine that binds to a heterodimeric receptor complex composed of the IFN-λ receptor 1 (IFNLR1) and interleukin-10 receptor 2 (IL10R2). This receptor complex is shared with other type III interferons. Upon binding to its receptor, IFN-λ4 activates the JAK-STAT signaling pathway, leading to the expression of interferon-stimulated genes (ISGs) that have antiviral effects.

The primary function of IFN-λ4 is to mediate antiviral responses, particularly in epithelial cells and hepatocytes. It plays a crucial role in the immune response to HCV and other viral infections, such as influenza and respiratory syncytial virus (RSV).

Clinical Significance[edit]

The presence of the ΔG allele, which allows the production of IFN-λ4, has been associated with a reduced ability to clear HCV infection spontaneously and a poorer response to interferon-based therapies. This has implications for the treatment and management of HCV, as patients with the TT allele tend to have better outcomes.

Research is ongoing to understand the broader implications of IFN-λ4 in other viral infections and its potential role in autoimmune diseases and cancer.

Research and Therapeutic Potential[edit]

The discovery of IFN-λ4 has opened new avenues for research into the mechanisms of viral clearance and the development of novel therapeutic strategies. Understanding the role of IFN-λ4 in the immune response could lead to the development of targeted therapies that modulate its activity to enhance antiviral immunity or reduce inflammation.

Also see[edit]